Koos E Hovinga1, Heather J McCrea1, Cameron Brennan1, Jason Huse2, Junting Zheng3, Yoshua Esquenazi1, Katherine S Panageas3, Viviane Tabar4. 1. Department of Neurosurgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA. 2. Department of Pathology, M.D. Anderson Cancer Center, Houston, TX, USA. 3. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 4. Department of Neurosurgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA. tabarv@mskcc.org.
Abstract
PURPOSE: The highly vascular malignant brain tumor glioblastoma (GBM) appears to be an ideal target for anti-angiogenic therapy; however, clinical trials to date suggest the VEGF antibody bevacizumab affects only progression-free survival. Here we analyze a group of patients with GBM who received bevacizumab treatment at recurrence and are stratified according to tumor molecular and genomic profile (TCGA classification), with the goal of identifying molecular predictors of the response to bevacizumab. METHODS: We performed a retrospective review of patients with a diagnosis of glioblastoma who were treated with bevacizumab in the recurrent setting at our hospital, from 2006 to 2014. Treatment was discontinued by the treating neuro-oncologists, based on clinical and radiographic criteria. Pre- and post-treatment imaging and genomic subtype were available on 80 patients. We analyzed time on bevacizumab and time to progression. EGFR gene amplification was determined by FISH. RESULTS: Patients with classical tumors had a significantly shorter time on bevacizumab than mesenchymal, and proneural patients (2.7 vs. 5.1 vs. 6.4 and 6.0 months respectively, p = 0.011). Classical subtype and EGFR gene amplification were significantly associated with a shorter time to progression both in univariate (p < 0.001 and p = 0.007, respectively) and multivariate analysis (both p = 0.010). CONCLUSION: EGFR gene amplification and classical subtype by TCGA analysis are associated with significantly shorter time to progression for patients with recurrent GBM when treated with bevacizumab. These findings can have a significant impact on decision-making and should be further validated prospectively.
PURPOSE: The highly vascular malignant brain tumor glioblastoma (GBM) appears to be an ideal target for anti-angiogenic therapy; however, clinical trials to date suggest the VEGF antibody bevacizumab affects only progression-free survival. Here we analyze a group of patients with GBM who received bevacizumab treatment at recurrence and are stratified according to tumor molecular and genomic profile (TCGA classification), with the goal of identifying molecular predictors of the response to bevacizumab. METHODS: We performed a retrospective review of patients with a diagnosis of glioblastoma who were treated with bevacizumab in the recurrent setting at our hospital, from 2006 to 2014. Treatment was discontinued by the treating neuro-oncologists, based on clinical and radiographic criteria. Pre- and post-treatment imaging and genomic subtype were available on 80 patients. We analyzed time on bevacizumab and time to progression. EGFR gene amplification was determined by FISH. RESULTS:Patients with classical tumors had a significantly shorter time on bevacizumab than mesenchymal, and proneural patients (2.7 vs. 5.1 vs. 6.4 and 6.0 months respectively, p = 0.011). Classical subtype and EGFR gene amplification were significantly associated with a shorter time to progression both in univariate (p < 0.001 and p = 0.007, respectively) and multivariate analysis (both p = 0.010). CONCLUSION:EGFR gene amplification and classical subtype by TCGA analysis are associated with significantly shorter time to progression for patients with recurrent GBM when treated with bevacizumab. These findings can have a significant impact on decision-making and should be further validated prospectively.
Authors: William F Elmquist; Jann N Sarkaria; Sani H Kizilbash; Shiv K Gupta; Karen E Parrish; Janice K Laramy; Minjee Kim; Gautham Gampa; Brett L Carlson; Katrina K Bakken; Ann C Mladek; Mark A Schroeder; Paul A Decker Journal: Mol Cancer Ther Date: 2021-03-30 Impact factor: 6.261
Authors: A F Cardona; L Rojas; B Wills; A Ruiz-Patiño; L Abril; F Hakim; E Jiménez; N Useche; S Bermúdez; J A Mejía; J F Ramón; H Carranza; C Vargas; J Otero; P Archila; J Rodríguez; J Rodríguez; J Behaine; D González; J Jacobo; H Cifuentes; O Feo; P Penagos; D Pineda; L Ricaurte; L E Pino; C Vargas; J C Marquez; M I Mantilla; L D Ortiz; C Balaña; R Rosell; Z L Zatarain-Barrón; O Arrieta Journal: Clin Transl Oncol Date: 2019-02-23 Impact factor: 3.340
Authors: Amir R Afshari; Mohammad Jalili-Nik; Mohammad Soukhtanloo; Ahmad Ghorbani; Hamid R Sadeghnia; Hamid Mollazadeh; Mostafa Karimi Roshan; Farzad Rahmani; Hamed Sabri; Mohammad Mahdi Vahedi; Seyed Hadi Mousavi Journal: EXCLI J Date: 2019-07-30 Impact factor: 4.068
Authors: Zammam Areeb; Sarah F Stuart; Alice J West; Juliana Gomez; Hong P T Nguyen; Lucia Paradiso; Ahmad Zulkifli; Jordan Jones; Andrew H Kaye; Andrew P Morokoff; Rodney B Luwor Journal: Sci Rep Date: 2020-10-20 Impact factor: 4.379